Language:

European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors

International journal of gynecological cancer, 2023-10, Vol.33 (10), p.1621-1626 [Peer Reviewed Journal]

IGCS and ESGO 2023. Re-use permitted under CC BY. Published by BMJ. ;2024 IGCS and ESGO 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;IGCS and ESGO 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. 2023 ;ISSN: 1048-891X ;ISSN: 1525-1438 ;EISSN: 1525-1438 ;DOI: 10.1136/ijgc-2023-004599 ;PMID: 37783481

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors
Author: Joneborg, Ulrika ; Bergamini, Alice ; Wallin, Emelie ; Mangili, Giorgia ; Solheim, Olesya ; Marquina, Gloria ; Casado, Antonio ; Rokkones, Erik ; Coulter, John ; Lok, Christianne A R ; van Trommel, Nienke ; Amant, Frédéric ; Bolze, Pierre-Adrien ; Sehouli, Jalid ; Han, Sileny ; Kridelka, Frédéric ; Goffin, Frederic ; Pautier, Patricia ; Ray-Coquard, Isabelle ; Seckl, Michael
Subjects: Cancer therapies ; Cervical cancer ; Chemotherapy ; Clinical trials ; Collaboration ; Data collection ; Disease ; Drug use ; Europe ; Female ; Genital Neoplasms, Female ; Genital Neoplasms, Female/diagnosis ; Genital Neoplasms, Female/therapy ; Gestational Trophoblastic Disease ; Gynecology ; Health Personnel ; Hospitals ; Human health sciences ; Humans ; Medicin och hälsovetenskap ; Meetings ; Obstetrics and Gynecology ; Off-Label Use ; Oncologie ; Oncology ; Original Research ; Ovarian cancer ; Ovarian Neoplasms ; Patients ; Sciences de la santé humaine ; Sex Cord-Gonadal Stromal Tumors ; Surveillance ; Trophoblastic Neoplasms ; Tumors
Is Part Of: International journal of gynecological cancer, 2023-10, Vol.33 (10), p.1621-1626
Description: ObjectiveTo evaluate outcomes of European cross-border multidisciplinary tumor boards in terms of participation, adherence to treatment recommendations, and access to novel treatment strategies.MethodsThe European reference network for rare gynecological tumors (EURACAN G2 domain) aims to improve the diagnosis, management, and treatment of patients with these cancers. Cross-border multidisciplinary tumor boards were initiated to facilitate intercollegiate clinical discussions across Europe and increase patients’ access to specialist treatment recommendations and clinical trials. All G2 healthcare providers were invited to participate in monthly multidisciplinary meetings. Patient data were collected using a standardized form and case summaries were distributed before each meeting. After each tumor board, a meeting summary with treatment recommendations was sent to all participants and the project manager at the coordinating center. The multidisciplinary tumor board format and outcomes were regularly discussed at G2 domain meetings. Anonymized clinical data and treatment recommendations were registered in a prospective database. For this report, clinical data were collected between November 2017 and December 2020 and follow-up data retrieved until May 2021.ResultsDuring the 3-year period, 31 multidisciplinary tumor boards were held with participants from 10 countries and 20 centers. 91 individual patients were discussed between one and six times for a total of 109 case discussions. Follow-up data were retrieved from 64 patients and 80 case discussions. Adherence to treatment recommendations was 99%. Multidisciplinary tumor board recommendations resulted in 11 patients getting access to off-label treatment and one patient being enrolled in a clinical trial in another European country. 14/91 patients were recommended for surveillance only when additional treatment had been considered locally.ConclusionCross-border multidisciplinary tumor boards enable networking and clinical collaboration between healthcare professionals in different countries. Surveillance strategies, off-label drug use, and increased participation in clinical trials are possible benefits to patients with rare gynecological tumors.
Publisher: Oxford: BMJ Publishing Group Ltd
Language: English
Identifier: ISSN: 1048-891X
ISSN: 1525-1438
EISSN: 1525-1438
DOI: 10.1136/ijgc-2023-004599
PMID: 37783481
Source: BMJ Open Access Journals
SWEPUB Freely available online
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

European multidisciplinary tumor boards support cross-border networking and increase treatment options for patients with rare gynecological tumors

Searching Remote Databases, Please Wait